Top Markets
#1 EXOD EXOD +9.04%
#2 MarsCoin MarsCoin +9.00%
#3 Akedo Akedo +8.33%
#4 Solstice Solstice +8.24%
#5 peaq peaq +8.13%
#6 ETHGas ETHGas +7.27%
#7 龙虾 (Lobster) 龙虾 (Lobster) +6.51%
#8 Wrapped Flare Wrapped Flare +6.34%
#9 Official Trump Official Trump +6.27%
#10 Peapods Finance Peapods Finance +6.22%
Coin of the day
EXOD EXOD
Setări
Limbă
ROMâNă
Monedă
USD
Temă
Intellia Therapeutics, Inc. Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc.

NTLA
Rang în acțiuni #6842
Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing... Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.
Preț acțiune
$13.15
Ultima sincronizare: 2026-08-27
Capitalizare de piață
$1.84B
Schimbare (1 zi)
-0.31%
Schimbare (1 an)
13.35%
Țară
US
Tranzacționează Intellia Therapeutics, Inc. (NTLA)

Categorie

Healthcare
Istoric al prețului acțiunii pentru Intellia Therapeutics, Inc. (NTLA)
Cel mai mare preț de închidere: $12.36 pe 2026-08-01

Cel mai mic preț de închidere: $26.53 pe 2016-05-01
Istoric al prețului acțiunii pentru Intellia Therapeutics, Inc. din 2016 până în 2026
Evoluția anuală a prețului acțiunii
An Performanță
2026 (TTM) 45.98%
2025 -30.41%
2024 -56.69%
2023 -19.53%
2022 -67.57%
2021 120.71%
2020 225.24%
2019 10.28%
2018 -24.22%
2017 26.96%
2016 0.00%
Prețul acțiunii pentru companii similare sau concurente
Companie Preț acțiune Variație 1an% Țara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $548.36 39.87%
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $1.06K 50.29%
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $121.16 -12.75%
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $140.81 475.44%
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 $765.25 7.74%
CH